OA of the knee-a prevalent condition that restricts daily activity

Approximately 27 million adults have reported being diagnosed with OA by their doctor. It is the most common form of arthritis in the United States. OA occurs when cartilage in joints breaks down over time. The breakdown of cartilage allows the bones to rub against each other, causing pain, stiffness, and loss of movement in the joint.

OA can happen in almost any joint; however, OA of the knee is the most common type.

THE EXACT CAUSE OF OA OF THE KNEE IS UNKNOWN, BUT YOU MAY BE AT RISK IF YOU:

  • Have a family history of OA
  • Are getting older
  • Are overweight
  • Do repetitive tasks, such as heavy lifting or kneeling

The pain and stiffness of OA of the knee can interfere with your everyday activities. To find out more, read How knee OA can affect your daily life.

Altman RD. Practical considerations for the pharmacologic management of osteoarthritis. Am J Manag Care. 2009;15:S236-S243. Arthritis Foundation. All about Osteoarthritis. http://www.arthritistoday.org. Accessed January 6, 2011. Arthritis Foundation. NSAIDs. Arthritis Today Drug Guide. http://www.arthritistoday.org/treatments/drug‑guide/types‑of‑drugs/drug‑guide‑nsaids.php. Accessed January 6, 2011. Arthritis Foundation. NSAIDs. Who gets osteoarthritis. http://www.arthritis.org/who‑gets‑osteoarthritis.php. Accessed January 6, 2011. Arthrotec (diclofenac sodium/misoprostol) Tablets USP [prescribing information]. New York, NY: G.D. Searle LLC, Division of Pfizer. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988;15:1833-1840. Diclofenac sodium delayed release tablets USP [prescribing information]. Corona, CA: Watson Laboratories, Inc. Evans JMM, McMahon AD, McGilchrist MM, et al. Topical non-steroidal anti-inflammatory drugs and admission to hospital for upper gastrointestinal bleeding and perforation: a record linkage case-control study. Br Med J. 1995;311:22-26. Heyneman CW, Lawless-Liday C, Wall GC. Oral versus topical NSAIDs in rheumatic diseases: a comparison. Drugs. 2000;60:555-574. Notman R, Noro M, O’Malley B, Anwar J. Molecular basis for dimethylsulfoxide (DMSO) action on lipid membranes. J Am Chem Soc. 2006;128:13982-13983. PENNSAID [package insert]. Mississauga, Ontario:Nuvo Research, Inc.; 2010.

INDICATION
PENNSAID® is a nonsteroidal anti-inflammatory drug (NSAID) used for treating the signs and symptoms of osteoarthritis of the knee(s).

IMPORTANT RISK INFORMATION

WARNING: CARDIOVASCULAR (CV) AND GASTROINTESTINAL (GI) RISK
    Cardiovascular Risk
  • Nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk of serious blood clots in the heart, or cause a heart attack or stroke. These risks can cause death. The risk may increase the longer NSAIDs are used. Patients who have heart disease or are at risk for heart disease may be at greater risk
  • Do not use PENNSAID in patients who are in the hospital for heart bypass surgery grafts
    Gastrointestinal Risk
  • NSAIDs cause an increased risk of serious stomach problems or problems in the intestines. Patients could bleed or develop a hole in their stomach or intestines. All of these problems can cause death. These problems can happen at any time with no warning when using NSAIDs. Older patients are at greater risk for these problems

COVIDIEN, COVIDIEN with logo and Covidien logo are U.S. and internationally registered trademarks of Covidien AG.
PENNSAID is a registered trademark of Nuvo Research Inc. Other brands are trademarks of their respective owners. © 2011 Covidien